Danish pharmaceutical firm Leo Pharma has entered a collaboration agreement with Canadian biotech firm Sequence Bio to use the latter’s proprietary discovery platform to identify dermatological targets, Sequence Bio has announced in a press release.
Sequence Bio is a commercial biotech company from Newfoundland. Under the terms of a three-year long deal, the company will be responsible for conducting a number of analyses of samples from cohorts across multiple dermatologic indications.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Long wait for IVDR implementation is over, putting an end to pandemic "wild west"
After prolonged debates on potential bottlenecking and supply issues, the EU’s long-awaited In Vitro Diagnostic Medical Devices Regulation comes into force on May 26.
GN purchase story is very speculative, says analyst
Competition rules could block a purchase of GN Store Nord and subsequent divestment of GN Hearing, says a Sydbank analyst on the speculative story that this might be underway.
Bavarian Nordic upgrades guidance following vaccine contract
Bavarian has been the center of attention in recent days due to its monkeypox vaccine, and the company has now secured a vaccine contract with another undisclosed country. Consequently, Bavarian has raised its expectations for the full year.
Novo Nordisk invests additional millions of dollars in new manufacturing facilities
Novo Nordisk’s DKK 17bn (USD 2.4bn) investment into upgrading and building new facilities in Kalundborg last year has now been followed by a DKK 1bn (USD 143.8m) investment in the same location.
US to start using Bavarian vaccine stockpile
In an attempt to contain a monkeypox outbreak, US authorities will start offering certain people Bavarian Nordic-developed Jynneos vaccinations against the infectious disease.
Communications Consultant 
Biostatistician 
Clinical Trial Manager for development of in vitro diagnostics 
System Sales Development Consultant - Investment Projects, Merck Millipore 
Senior IT Network Engineer 
Innovation Project Manager, Display Unit 
Senior Manager, Clinical Trial Budget 
Account Manager 
Clinical Trial Manager 
Senior Chemical Safety Advisor 
Analytical Senior Scientist 
Director for innovative pre-clinical testing unit 
Nordic Medical Affairs Manager 
Consultant Manager 
Client Talent Acquisition Specialist 
Production Director 
CMO Operations Specialist - screening & selection of CMO/CDMO’s